<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041782</url>
  </required_header>
  <id_info>
    <org_study_id>ID00-078</org_study_id>
    <nct_id>NCT00041782</nct_id>
  </id_info>
  <brief_title>Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients</brief_title>
  <official_title>Outpatient Treatment Of Deep Venous Thrombosis (DVT) Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brookdale University Hospital Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Josephine Ford Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Plan: Adult cancer patients who have a low risk profile and present with DVT will&#xD;
      receive dalteparin 200 IU/kg subcutaneously daily (based on actual body weight with a maximum&#xD;
      dose of 18,000 IU). Eligible patients who have signed the informed consent will be instructed&#xD;
      on injection technique, will give themselves their first subcutaneous injection under&#xD;
      supervision of the physician or the nurse and will be observed for a minimum of 1-2 hours&#xD;
      prior to discharge. Patients may be admitted to an observation unit for up to 24 hours prior&#xD;
      to discharge if medically necessary. Those patients without complications during the&#xD;
      observation period will be given discharge instructions and an outpatient schedule to see one&#xD;
      of the physician investigators daily for their subcutaneous injection of dalteparin, routine&#xD;
      lab work and initiation of oral anticoagulation therapy.&#xD;
&#xD;
      Patients that are proficient in administering their own injection with dalteparin will be&#xD;
      evaluated every other day by the physician investigator. On days of home injection, the study&#xD;
      nurse will call the patient to check on the patient's status and to remind the patient of&#xD;
      his/her daily injection. Patients will undergo a physical examination every other day by the&#xD;
      physician investigator directed towards the clinically affected areas until a therapeutic&#xD;
      response (INR 2-3) on oral warfarin has been achieved or the patient's clinical condition&#xD;
      warrants modification of therapy with or without hospitalization. Patients will remain on&#xD;
      study for a minimum of 5 days with at least 1 day of therapeutic oral anticoagulation.&#xD;
&#xD;
      The quality of life of the patients enrolled will be assessed by using the Modified Medical&#xD;
      Outcome Study Short Form-20. An adapted version of the Rotterdam Symptom Checklist will be&#xD;
      used to specifically assess patients with thrombosis. Patients will complete these two&#xD;
      instruments at study entry, day 3, day 5 and at the end of study if different from day 5.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 2000</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life Survey Responses</measure>
    <time_frame>Collection over study period (5 years)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Neoplasms</condition>
  <condition>Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Dalteparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin (Fragmin)</intervention_name>
    <description>200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).</description>
    <arm_group_label>Dalteparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Cancer patients with documented DVT and meeting eligibility criteria will be entered on the&#xD;
        study if they consent to participate.&#xD;
&#xD;
        Patients eligible for the study will include:&#xD;
&#xD;
          -  Patients with solid tumors (including lymphoma and myeloma).&#xD;
&#xD;
          -  Patients with clinical and venographic or ultrasonographic evidence of thrombosis of&#xD;
             the proximal or distal lower or upper extremity.&#xD;
&#xD;
          -  Patients with catheter-related thrombosis will be eligible for the study if they are&#xD;
             not candidates for thrombolytic therapy.&#xD;
&#xD;
          -  Patients with Zubrod performance status of &lt;2. (Appendix A)&#xD;
&#xD;
          -  Patients with adequate bone marrow function: platelets &gt;100,000/mm3, and ANC &gt;1,500&#xD;
             cells/mm3.&#xD;
&#xD;
          -  Patients with adequate renal function: creatinine &lt; 2.5 mg/dL.&#xD;
&#xD;
          -  Patients with adequate liver function: SGPT &lt; 1.5 x upper limit of normal, alkaline&#xD;
             phosphatase &lt; 2.5 x upper limit of normal, bilirubin &lt; 1.5 mg/dL.&#xD;
&#xD;
          -  Patients must have caregiver available and willing to assist with care and&#xD;
             transportation for the first 72 hours of the study period.&#xD;
&#xD;
          -  Patients must have a telephone within the home.&#xD;
&#xD;
          -  Patients must live or stay within a 30-mile radius of the study site.&#xD;
&#xD;
          -  Patients must have a history of compliance with outpatient therapy and follow-up&#xD;
             visits.&#xD;
&#xD;
          -  Patients must be able to read to complete study instruments.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        A patient must not be enrolled if any of these criteria apply:&#xD;
&#xD;
          -  Prior history of DVT or PE in the past year.&#xD;
&#xD;
          -  Evidence of active bleeding, active peptic ulcer disease, or a familial bleeding&#xD;
             disorder proven with a diagnostic study.&#xD;
&#xD;
          -  A Hemoglobin of 7.5 or less.&#xD;
&#xD;
          -  Concurrent symptomatic PE in the past year.&#xD;
&#xD;
          -  Currently receiving treatment with UFH for DVT.&#xD;
&#xD;
          -  An inability to be treated with LMWH as an outpatient because of comorbidities or&#xD;
             clinical condition requiring hospitalization: (cerebral vascular accident,&#xD;
             uncontrolled diabetes mellitus, uncontrolled hypertension, new onset atrial&#xD;
             fibrillation, chronic obstructive pulmonary disease with dyspnea, and / or trauma).&#xD;
&#xD;
          -  Hypotension (systolic blood pressure &lt; 90 mm Hg).&#xD;
&#xD;
          -  Tachypnea (respiratory rate &gt; 30/min.).&#xD;
&#xD;
          -  Altered sensorium.&#xD;
&#xD;
          -  Uncontrolled hypercalcemia (Corrected calcium &gt; 12mg/dL).&#xD;
&#xD;
          -  Hyponatremia (serum sodium &lt; 128 mg/dL).&#xD;
&#xD;
          -  Women who are pregnant or nursing.&#xD;
&#xD;
          -  Expected decrease in the platelet count of less than 50,000 during the next 10 days&#xD;
             following entry.&#xD;
&#xD;
          -  Patients with the presence of known deficiency of antithrombin III, protein C, or&#xD;
             protein S.&#xD;
&#xD;
          -  Patients with known history of activated protein C resistance.&#xD;
&#xD;
          -  Patients on oral anticoagulants (anisindione, dicumarol or warfarin) and/or platelet&#xD;
             inhibitors (aspirin, abciximab, alprostadil, dipyridamole, sulfinpyrazone, ticlopidine&#xD;
             or NSAIDS) that could affect hemostasis.&#xD;
&#xD;
          -  Patients with previous heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Patients with epidural catheters.&#xD;
&#xD;
          -  Patients with a hypersensitivity reaction of UFH, dalteparin or porcine products.&#xD;
&#xD;
          -  Patients with known non-compliance with previous treatment regimens.&#xD;
&#xD;
          -  Patients with primary central nervous system tumors, brain metastases or evidence of&#xD;
             leptomeningeal disease.&#xD;
&#xD;
          -  Treatment Plan (Appendix B)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmelita P. Escalante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 16, 2002</study_first_submitted>
  <study_first_submitted_qc>July 18, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2002</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Vein Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

